Clinical Trial Contact Request

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Please complete the form below to be contacted by our Clinical Trial Information Service
 (1024)
By submitting this form, you accept our Terms & Conditions and grant permission for us to contact you. We will not sell or share your information (Privacy Policy). Please do not submit another person’s name or email without his or her consent.